The French multicentric molecular analysis platforms and personalized medicine trials MOST, MOST Plus and MEGAMOST — Loïc Verlingue (2024) | RDL Network
The French multicentric molecular analysis platforms and personalized medicine trials MOST, MOST Plus and MEGAMOST
Article 2024 en
Authors
LV
Loïc Verlingue
MD
Marine Desevre
MP
M. Polito
Abstract
1 min read
PROFILER has recruited 5,991 patients in 10 years, MOST and MOST Plus 875 patients since 2014 and MEGAMOST 172 patients since 2020, and are still ongoing. We provide a description of the local, national and international implications of these initiatives, and we review the results of the sorafenib and olaparib cohorts.
Olivier Trédan, Maud Toulmonde, Christophe Le Tourneau, Laure Montané, Antoîne Italiano, Isabelle Ray‐Coquard, Christelle de la Fouchardière, François Bertucci, Anthony Gonçalvès, Carlos Gomez‐Roca, Benoît You, Valéry Attignon, Sandrine Boyault, Philippe A. Cassier, Armelle Dufresne, Séverine Tabone‐Eglinger, Alain Viari, Emilie Sohier, Maud Kamal, Gwenaëlle Garin, Jean Yves Blay, David Pérol
Philipp K. Haber, Marc Puigvehí, Florian Castet, Vennis Lourdusamy, Robert Montal, Parissa Tabrizian, Michael Buckstein, Edward Kim, Augusto Villanueva, Myron Schwartz, Josep M. Llovet
Tereza Vaclová, Nicholas T. Woods, Fernando Setién, José María García Bueno, José A. Macías, Alicia Barroso, Miguel Urioste, Manel Esteller, Álvaro N.A. Monteiro, Javier Benı́tez, Ana Osório
Paul Sargos, Marie Pierre Sunyach, Anne Ducassou, C. Llacer, Carine Bellera, Audrey Michot, Thibaud Valentin, Nelly Firmin, Jean Yves Blay, Derek Dinart, Antoîne Italiano
Cathrine Axfors, Andreas M. Schmitt, Perrine Janiaud, Janneke van ’t Hooft, Sherief Abd‐Elsalam, Ehab Fawzy Abdo, Benjamin S. Abella, Javed Akram, Ravi K. Amaravadi, Derek Angus, Yaseen M. Arabi, Shehnoor Azhar, Lindsey R. Baden, Arthur W. Baker, Leïla Belkhir, Thomas Benfield, Marvin A. H. Berrevoets, Cheng‐Pin Chen, Tsung‐Chia Chen, Shu‐Hsing Cheng, Chien‐Yu Cheng, Wei‐Sheng Chung, Yehuda Z. Cohen,
Discussion(0)
No comments yet. Be the first to comment.